An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the ECCMID 2019. To view the poster, please, click here. Congratulations to the authors!
The 7th newsletter is available here. This issue announces Ebovac2 4th annual meeting in Nairobi (Kenya) in January 2019.
The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.
Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.
Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here : http://www.bbc.co.uk/news/uk-39202974
The joint EBOVAC1 and EBOVAC2 annual meeting took place in Windsor, UK from 14-16 November 2016.
What is Ebola?
Find out more about EBOVAC2 trials
EBOVAC2 is organised into 6 workpackages (WP)
Contributes to efforts to tackle a wide range of challenges in Ebola research